Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Blood (2013) 122 (17): 3034–3044.

https://doi.org/10.1182/blood-2013-04-495374

Published: 2013

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2494.

https://doi.org/10.1182/blood.V118.21.2494.2494

Published: 2011

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Jason G Harb, Paolo Neviani, Joshua J Oaks, Guido Marcucci, MD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 1222.

https://doi.org/10.1182/blood.V116.21.1222.1222

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Anna M. Eiring, Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Ji Suk Chang, Mario Notari, William Willis, Carlo Gambacorti-Passerini, Stefano Volinia, Guido Marcucci, Michael A. Caligiuri, Gustavo W. Leone, Danilo Perrotti

Blood (2008) 111 (2): 816–828.

https://doi.org/10.1182/blood-2007-05-090472

Published: 2008

Journal Articles

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Joshua J. Oaks, BS, Ramasamy Santhanam, Ph.D., Roger Briesewitz, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 3548.

https://doi.org/10.1182/blood.V110.11.3548.3548

Published: 2007

Journal Articles

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

Anna M. Eiring, BS, Paolo Neviani, D.Sci., Ramasamy Santhanam, Ph.D., Joshua J. Oaks, B.S., Ji Suk Chang, Ph.D., Carlo Gambacorti-Passerini, MD, Stefano Volinia, MD, Guido Marcucci, MD, Michael A. Caligiuri, MD, Gustavo W. Leone, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 33.

https://doi.org/10.1182/blood.V110.11.33.33

Published: 2007

Journal Articles

ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.

Paolo Neviani, MS, Ramasamy Santhanam, Ph.D, Rossana Trotta, Ph.D, Mario Notari, MS, Bradley W. Blaser, BS, Ji-Suk Chang, Ph.D, Shujun Liu, Ph.D, Hsiaoyin Mao, MS, Joshua J. Oaks, BS, Denis C. Roy, MD, Mauro Valtieri, MD, Rebecca Bruner-Klisovic, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2005) 106 (11): 1992.

https://doi.org/10.1182/blood.V106.11.1992.1992

Published: 2005

NARROW

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only